Read your latest personalised notifications
No account yet? Start here
Don't miss out
Ok, got it
Take the opportunity to meet Internationally renowned experts in your field.
HFA Career Café 2019 is the meeting place for the future generation of cardiologists to interact with the great leaders of their specialty.
During individual interviews of 12 minutes, the selected applicants have the privilege to seek career development advice and recommendations from renowned professionals with years of successful careers behind them.
This is a unique platform where long-lasting generational relationships are possible!
HFA Career Café 2019 will take place in the HFA Career Café area (opposite the HFA stand) on:
Applicants have to be:
IMPORTANT: Applicants must be sure not to have any conflicting role at the same time.
To apply, please follow the below instructions:
Deadline: Sunday 5 May 2019 (23:59)
Deadline: Sunday 5 May 2019 (23:59)
Results will be given in the third week of May.
Areas of expertiseHeart failure, trials, pathophysiology, cachexia
BiographyStefan D. Anker is Professor of (Tissue) Homeostasis in Cardiology & Metabolism (W3) at Charité Berlin (from June 2017). Dr. Anker studied medicine at Charité Berlin and completed his clinical training in Germany and the UK. He obtained his M.D. from Charité Medical School, Berlin, Germany (1993), and his Ph.D. (1998) at National Heart & Lung Institute of Imperial ollege London. He was Professor of Cardiology & Cachexia Research (W2) at Charité (2002-14), and Professor of Innovative linical Trials (W3) in Göttingen (2014-17).
Dr. Anker has authored more than 800 original papers, reviews, and editorials that are well cited (total citations: >66,000, h-index: 115, papers with ≥ 200 citations: 80; source: Scopus, 20th Jan, 2019). For his work Dr. Anker has won several prizes, including the 2018 Copernicus Prize of German DFG & Polish FNP. He obtained a number of fellowships & grants, incl. 2 from NIH (WARCEF EU), 2 EU-FP7 & 2 IMI/Horizon2020 grants. He was co-ordinator for “SICA-HF” (EU-FP7). He received grants for three IITs that are currently running for >15 Mill EUR (from DZHK Germany & several industries).
Dr. Anker was Vice President of the European Society of Cardiology (ESC, 2016-18), serving on the ESC board 2012-2018. Dr. Anker serves in the board of the Heart Failure Association (HFA) of the ESC since 2006; he was HFA President (2012-14). He is founding Editor-in-Chief of the open access journal ESC Heart Failure. Dr. Anker worked in several ESC Guideline task forces (e.g. the ESC HF guidelines 2012 & 2016).Dr. Anker is the founding president of the International Society on Sarcopenia, Cachexia and Wasting Disorders since 2008 (SCWD – see www.cachexia.org). Dr. Anker is founding Editor-in-Chief of the Journal of Cachexia, Sarcopenia and Muscle since 2010 (JCSM, 2017-IF: 12.51, see www.jcsm.info).
Dr. Anker was and is member of >30 international clinical trial steering committees, chairing or co-chairing several currently (FAIR-HF2, EMPEROR-HFpEF, Fair-HFpEF, EMPERIAL-HFpEF, RELIEVE-HF, REVIVE-HF) as well as in the past (incl. FAIR-HF, TIM-HF, AUGMENT-HF, IMPULSE-HF & BACH). He served in a number of DMC’s (chairing 4) and end-point committees (chairing 4).
Area of expertiseAcute and chronic heart failure, left ventricular healing and remodelling, peripartum cardiomyopathy, translational studies
Professor Bauersachs studied Medicine at the University of Freiburg. After training as Clinical and Research Fellow at the Universities of Frankfurt and Heidelberg/Mannheim, in 1999 he moved to the University Hospital Wuerzburg where he became Consultant and Lecturer in Internal Medicine and Cardiology and was Associate Professor in the Department of Medicine from 2008 to 2010. Since 2010 he is Full Professor and Director of the Department of Cardiology and Angiology at Hannover Medical School.
Professor Bauersachs is an interventional cardiologist with special interests in acute coronary syndromes, left ventricular healing and remodeling, acute and chronic heart failure, as well as intensive care. He is particularly interested in the pathophysiology and treatment of peripartum cardiomyopathy, in aldosterone and mineralocorticoid receptor-mediated mechanisms, and the role of non-coding RNAs. He is Study Chair of the DIGIT-HF study investigating the effect of Digitoxin on morbidity/mortality in patients with advanced heart failure.
Professor Bauersachs is Fellow and Board Member of the Heart Failure Association (HFA) of the ESC, Chair of the HFA Clinical Science Section, and Chair of the HFA Study Group on Peripartum Cardiomyopathy. He is Chair of the Cardiovascular Section of the Fachkollegium Medizin, Deutsche Forschungsgemeinschaft (DFG), and Speaker of the Clinical Research Group (KFO) 311 “(Pre-) terminal heart and lung failure - mechanical unloading and repair” funded by the DFG.
Areas of expertiseEchocardiography, Cardiac magnetic resonance, Computed tomography, Nuclear imaging
BiographyESC Immediate Past-President (2018 – 2020), Jeroen Bax is Director of non-invasive imaging and Director of the echo-lab at the Leiden University Medical Center. His main interests include clinical cardiology, heart failure, cardiac resynchronization therapy and the application of all different imaging modalities to these clinical fields. Professor Bax has authored numerous papers and holds several positions in national and international scientific organizations, as well as serving on the editorial boards of many different journals.
Areas of expertiseAtrial fibrillation, Redox biology
BiographyBarbara Casadei is a British Heart Foundation (BHF) Professor of Cardiovascular Medicine, University of Oxford; Honorary Consultant Cardiologist, Oxford University Hospitals NHS Trust’s John Radcliffe Hospital; Lead, Myocardial Theme, Oxford BHF Centre of Excellence; and Lead, Cardiovascular Theme, Oxford NIHR Biomedical Research Centre. She is a Fellow of the UK Academy of Medical Sciences, President, European Society of Cardiology (ESC) and leads a bench-to-bedside translational research programme, spanning from clinical trials to bench-based investigation in human tissue and cells.
Heart failure, extending from its epidemiology and prevention, through the development and implementation of guidelines for the application of current knowledge, to large randomized trials. Particular current interests include the influence of myocardial and renal substrate on therapeutic response, novel methods of delivering care and theranostics.
Areas of expertise
Clinical management of patients with heart failure
University of Bergen, Stavanger University Hospital, Stavanger, Norway. Kenneth Dickstein was born in Philadelphia and completed undergraduate education at the Univ. of Pennsylvania. He has medical degrees from the Univ. of London and the Royal College of Surgeons in Dublin. He was a research fellow at Harvard Medical School (1988-90) and completed his PhD in exercise physiology at the Univ. of Bergen in 1992. Professor Dickstein was in charge of the coronary care unit at Stavanger University Hospital, full professor of medicine at the Univ. of Bergen and was coordinator for the medical student teaching program at the hospital. His primary focus is clinical research in heart failure with an interest in both pharmacologic therapy and the use of cardiac devices in patients with heart failure. Professor Dickstein is a Past-President of the Heart Failure Association of the European Society of Cardiology and has been a councillor on the ESC Board. He was Chairman of the Task Forces for two of the ESC Guidelines on Heart Failure. In 2016, he received the National Research Prize from the Norwegian National Society and the Falch Research Prize from the University of Bergen in 2017. Prof. Dickstein has been an author on over 370 scientific papers and held over 400 invited lectures at international venues. He is the founder of the ESC patient website heartfailurematters.org, is a member of numerous editorial boards and steering committees and is an active associate editor of the European Journal of Heart Failure. He resides with his wife and 2 sons on the west coast of Norway and spends his summers fly fishing.
Inger Ekman was awarded a PhD degree at Umeå University in 1999. In 2007, she was appointed full professor of Care Sciences at Sahlgrenska Academy, University of Gothenburg. During the period 2006-2010, she was Head of Institute of the Institute of Health and Care Sciences, and 2010-2012 she was Vice Dean at the Sahlgrenska Academy (The University of Gothenburg Medical Faculty). Since 2010, Inger Ekman is also the Director of the University of Gothenburg Centre for Person-Centred Care - GPCC (www.gpcc.gu.se).Inger Ekman's research focuses on communication and symptoms in patients with long term illness, and evaluation of person-centred care interventions.
Inger Ekman has had in excess of 120 articles published in scientific journals.Ekman is also since 2016 the coordinator of COST CARES (http://www.cost.eu/COST_Actions/ca/CA15222 ), a European initiative, involving 28 countries, which tests the implementation of person-centred care and health promotion within the frame of cost containment with maintained or improved quality of care using testbeds in five countries. Inger also co-ordinated this project’s precursor We Care, in which European key players from academy, health care, business, patient organisations and politics developed a R & I road map on which the current project is based.
Lecturer and examiner in PhD level course “The concept ”Person” and person-centred care – philosophical foundation “ at Sahlgrenska University Hospital. Frequent lecturer at major national and international conferences and implementation of person-centred care programmes in health care settings.
Clinical research and member of Sahlgrenska University Hospital/Östra Steering Group, and supports the implementation in Person-centred care at the whole of Sahlgrenska University Hospital.
Arno W. Hoes studied medicine at the Radboud University Nijmegen. He obtained his PhD degree at Erasmus University Rotterdam and was trained in Clinical Epidemiology at Erasmus Medical Center Rotterdam and the London School of Hygiene and Tropical Medicine.In 1998 he was appointed professor of Clinical Epidemiology and General Practice at the Julius Center for Health Sciences and Primary Care of the University Medical Center in Utrecht. Since 2010, he is the Chair of the Julius Center.
His clinical research topics include the diagnosis, prognosis and therapeutic interventions in cardiovascular disease, and, in particular, heart failure. Many of his studies in heart failure are conducted in the primary care setting and focus on improving early diagnosis and prognosis of heart failure.
He is involved in many ESC activities and especially the HFA: he is a board member of the HFA and chairs its Patient Care Committee. Professor Hoes has been (co-)applicant of many research grants. He has (co-)authored over 500 papers in peer-reviewed journals (Hirsch index 68) and more than 50 PhD students completed their PhD thesis under his supervision.
Areas of expertiseHF disease management, research, nursing
BiographyProf. Dr. Tiny Jaarsma (RN NFESC FAHA FAAN) is a HFA board member and professor in caring sciences/nursing science at the University of Linköping, Sweden and the University of Utrecht (NL). My research focuses on the consequences of heart failure for patients and their families and developing and testing interventions to enhance their self-care. I study and teach about optimal heart failure management programs and am editor-in chief of the European Journal of Cardiovascular Nursing.
Area of expertisePharmacology of heart failure, neuro-hormones in heart failure, genetics of dilated and hypertrophic cardiomyopathy.
BiographyMichel KOMAJDA was Professor of Cardiology at the University Pierre et Marie Curie - Paris VI/Hospital Pitié Salpétrière, Paris, France from 1990 to 2017.
He was Head of the Department of Cardiology, Pitié Salpêtrière Hospital (Paris) and of the cardio-metabolic division (2006-2014).He is consultant in the department of cardiology Saint Joseph hospital in ParisHe is a member of the research Unit INSERM UMRS 1166, of the Institut Hospitalo-Universitaire ICAN.
He is member of the Académie Nationale de Médecine since 2012 and chair of the Board of the Fondation Coeur et Recherche since 2014.
Michel Komajda’s mains fields of interest are pharmacology of heart failure, neuro-hormones in heart failure, genetics of dilated and hypertrophic cardiomyopathy.He was President of the European Society of cardiology in 2010-2012. He occupied several key positions including Vice-President of the ESC Working Groups, Association and Councils (2006-2008), and Chairman of the ESC Programme Committee in 2005-2006 in the ESC. He was also Co-Chairman on the “Euro Heart Failure Survey I” and Member of the Executive Committee of “Euro Heart Failure Survey II” Programmes. He occupied the positions of Treasurer and General Secretary of the French Society of Cardiology and was President of this Society in 2002-2003.
He is member of the Editorial Boards of European Heart Journal, European Journal of Heart Failure and Circulation.
Michel Komajda is the author of over 300 peer-reviewed papers, mostly in heart failure and has collaborated in several Steering, Executive Committees, Adjudication Committees or DSMBs of international trials on heart failure and cardiovascular diseases (CARMEN, COMET, I-PRESERVE, HEAAL, RECORD, CORONA, SHIFT, PARADIGM HF, PARAGON, PARALLEL, RELAX AHF 2, PARADISE, COLCOT).
Dr Kotecha is a Clinician Scientist in Cardiovascular Medicine at the University of Birmingham, a Consultant Cardiologist specialising in cardiac imaging, and holds a prestigious National Institute for Health Research (NIHR) Career Development Fellowship. In 2018, he was awarded the British Cardiovascular Society Michael Davies Award for his contribution to cardiovascular medicine, in particular relating to atrial fibrillation and heart failure.
Dr Kotecha has a diverse research portfolio, with expertise in robust statistical evaluation and trial methodology, ‘Big Data’, cardiac imaging, therapeutics, patient involvement and novel technology, such as mobile applications and wearable devices. His work has been published in leading journals such as the Lancet, BMJ and European Heart Journal, and he has received funding from the NIHR, British Heart Foundation and European Union.
Dr Kotecha works with the European Society of Cardiology (ESC) on the Education and Congress Planning Committees, and helped to write the 2016 ESC Guidelines for the Management of Atrial Fibrillation. He supervises a number of PhD students including basic, translational and clinical science, leads an international heart failure consortium (the Beta-blockers in Heart Failure Collaborative Group), and is Chief Investigator of the first randomised controlled trial of digoxin in patients with atrial fibrillation and symptoms of heart failure (RATE-AF).
Ekaterini Lambrinou is an associate professor and the first elected academic staff at the Department of Nursing of the Cyprus University of Technology.
She holds a PhD in Gerontology Nursing, a Master’s in Clinical Nursing and a BSc from the University of Athens. She has been a visiting lecturer at the Faculty of Nursing of the University of Athens and the University of Peloponnese. Her professional clinical experience was in intensive care units, mainly in the intensive care unit at the 1st Cardiology Department of Athens Medical School, at the Hippocration Hospital in Greece, where she gained great experience on the care of people with cardiovascular diseases.
Over the years, she contributed to several undergraduate and postgraduate courses, mainly focusing in medical nursing and specialties, acute and intensive cardiology care and gerontology nursing. With a background in gerontology, and intensive cardiology care, her research interests include: nurses’ role in the strategies of prevention and management of patients with cardiovascular diseases and comorbidities. Heart failure management is her main interest since it is one of the most common health problems of older people. Most of her publications and citations are referred to the particular topic, including high impact journals.
Over the last six years she has been very involved within the activities of the European Society of Cardiology. She sat on the Board of the European Heart Failure Association (2012-16) and she has been the Chair of the Council of Cardiovascular Nurses and Allied Professions (2016-18). She is currently the past-Chair of the Association of Cardiovascular Nurses and Allied Professions (2018-20) of the ESC.
Areas of expertiseHeart failure, Cardio-Oncology and Takotsubo syndrome
BiographyAlexander Lyon is a Senior Lecturer in Cardiology at Imperial College London and a Consultant Cardiologist at the Royal Brompton Hospital. Dr Lyon is a current member of the HFA board and chair of the HFA Cardio-Oncology and Takotsubo Syndrome Study Groups. Dr Lyon is president of the British Cardio-Oncology Society which is hosting the Global Cardio-Oncology Summit in London in September 2017. Dr Lyon studied Medicine at Oxford University and he completed his PhD in gene therapy for heart failure at Imperial College London.
Prof. Alexandre Mebazaa is Professor of Anaesthesiology and Critical Care Medicine at the Hôpital Lariboisière, University Paris 7, France. Prof. Mebazaa qualified from the Louis Pasteur University, Strasbourg, France, and subsequently obtained a doctorate on the effect of endothelial cells on the calcium responsiveness of the cardiac myofilament from the Lariboisière School of Medicine, Paris. His research interests include mechanisms of contractile impairment during acute heart failure. He acted as member or Chair of several Steering Committee of agents tested in acute heart failure setting. He is also heavily involved in several European and global registries on circulatory failure. He authored or coauthored more than 300 papers and is Lead Editor of the “Acute Heart Failure” book. He is acting as Chair of Department of Anesthesiology and Critical Care in Paris.
Biomarkers, acute heart failure, clinical research, mentoring, team-building
Director, Cardiovascular Research Institute Basel (CRIB); Professor of Cardiology, Internal Medicine and Intensive Care Medicine, University Hospital Basel, Switzerland
Dr. Mueller obtained his medical degree from the University of Munich, Germany in 1995, and performed his postgraduate training in internal medicine, intensive care medicine, and cardiology in Germany and Switzerland. With the support of the Swiss National Science Foundation and the Swiss Heart Foundation, he was able to establish his own research group at Basel University Hospital in 2000. His research aims to improve the early diagnosis and management of cardiovascular disorders, particularly heart failure and myocardial infarction. He was awarded a SNF professorship at Basel University in 2004, and promoted to full professor in 2011. Dr. Mueller is co-founder of the CRIB, member of several ESC experts committees, president of the GREAT network, and associate editor for the European Heart Journal and European Heart Journal Acute Cardiovascular Care. He is well published in the medical literature, with more than 500 original contributions published in international peer-reviewed journals.
Areas of expertiseInterventional cardiology, observational studies , biostatistics, takotsubo syndrome, acute heart failure, preclinical models of myocardial infarction and heart failure
BiographyElmir Omerovic is a senior consultant cardiologist and Professor of Cardiology at Göteborgs University. Since 2007 he is head of the Heart Group at The Wallenberg Laboratory for Cardiovascular research at Sahlgrenska Academy, Gothenburg, Sweden. Professor Omerovic is a board certified cardiologist with training at the Sahlgrenska University Hospital. He has a broad clinical and scientific interest in the entire field of cardiovascular medicine from prevention (hypertension, lipid disorders, diabetes) to coronary artery disease (angina pectoris, myocardial infarction, acute post-infarction heart failure) to chronic heart failure. His special research interest is taktosubo syndrome and observational studies based on national registries of cardiovascular diseases in Sweden (SWEDEHEART/SCAAR). He is trained interventional cardiologist regularly performing diagnostic coronary angiographies and percutaneous coronary procedures.
Areas of expertiseCardiovascular Pharmacology and Heart Failure
BiographyMD in Medicine and Surgery at the La Sapienza University of Rome with full honors in 1988, Specialization in Cardiology in 1992PhD in Medical Sciences from the Imperial College in LondonHe has authored over 400 peer-reviewed articles, 5 books and 28 book chapters.
He currently serves as an expert in the area of Cardiovascular Medicine for the European Assessment Office of the Italian Drug Agency (AIFA), he is core member of the Cardiovascular Working Party of the European Medicines Agency.
He is board member of the Heart Failure Association (HFA) and Nucleus member of the Working Group on Cardiovascular Pharmacotherapy of the ESC.
Areas of expertiseHeart failure, cardiovascular disease in pregnancy, population studies
Professor Karen Sliwa is a Professor at the Hatter Institute for Cardiovascular Research in Africa (HICRA) at the University of Cape Town. As the Director of HICRA she leads several research groups.
Born in Germany, she is a clinician-scientist, having trained in Germany, Scotland and Israel. In 1992 Karen immigrated to South Africa where she completed her clinical training as a specialist physician, cardiologist and obtained a Diploma in Tropical Medicine and Hygiene. In 2002 she was awarded a PhD from the University of the Witwatersrand and she contributed to > 250 peer-reviewed articles and trained > 30 postgraduate students so far.
Professor Sliwa is highly experienced in developing, designing and leading cardiovascular disease (CVD) studies in various healthcare environments in Africa. She devised innovative strategies to raise funds through numerous sources at a time when very limited funding was available for non-communicable disease (NCD) research. Her seminal Heart of Soweto Study, reporting on the prevalence, presentation and management of cardiac disease in an urban African population (8000 patients), published in the Lancet in 2008 led to >25 publications describing e.g. the impact of HIV/AIDS on CVD, the prevalence of rheumatic heart disease diagnosed in adulthood, and the spectrum of conditions leading to heart failure amongst others. These studies underpin Prof Sliwa’s status as a world-recognized expert in cardiac conditions common in Africa. Her fundamental role as an innovative leader in the field has been further highlighted in published profiles in the Lancet (2014) and European Heart Journal (2015, 2017). Under the umbrella of the ‘Heart of Africa Studies’, cardiovascular population studies have been expanded to other African countries by her design and implementation of several innovative research programs and her ability to leverage funding for these projects.
Prof. Karen Sliwa leads a large international registry on peripartum cardiomyopathy (PPCM), funded by the European Cardiac Society (EORP PPCM). She is well known for her research in the area of cardiac disease in the peripartum period which lead to more than 20 publications in that field including the Lancet (2016). She is an editorial consultant/ board member of a number of prestigious journals including ‘The Lancet’ and the European Heart Journal, Nature Review Cardiology and European Journal Heart Failure.
Prof. Karen Sliwa received Fellowships from the American College of Cardiology ( ACC), the European Society of Cardiology (ESC) and hold honorary research appointments at the Population Health Research Institute (PHRI), Hamilton, Canada and the Baker Institute, Melbourne, Australia amongst others. She holds numerous awards such as Honorary Doctorate University Diderot-Sorbonne, Paris, France (this is the highest distinction of French Universities as a recognition towards Research and Global Engagement which is awarded by the French University Research Board and approved by the French Ministry of Foreign affairs). The German Cardiac Society Paul Morawitz Award for Exceptional Cardiovascular Research (this distinguished award is given once per annum for exceptional research in cardiology & cardiothoracic surgery in Germany, Austria and Switzerland).
She was elected as President-Elect of the World Heart Federation in 2017 and has commenced office January 2019.
Chronic heart failure, Interventions, Clinical Trials
Karl Swedberg is Senior Professor of Cardiology and Care Sciences, Sahlgrenska Academy, University of Gothenburg, Sweden and Professor of Cardiology, National Heart and Lung Institute, Imperial College, London. His research interests include beta-blockers and angiotensin-converting enzyme inhibitors (ACEIs) and their effects in heart failure (HF) and myocardial infarction (MI), neuroendocrine activation in HF and the treatment of chronic HF. Professor Swedberg was the first to report on the survival benefits of a beta-blocker (1979), ACEI (1987) and angiotensin receptor blocker (2003) in chronic HF. He has published widely with more than 600 manuscripts in peer-reviewed journals. Professor Swedberg received the European Society of Cardiology Gold Medal 2007 for his outstanding contributions to the cardiovascular field and in 2016 the Lifetime Achievement Award from Heart Failure Association (HFA). Professor Swedberg was Editor-in-Chief of European Journal of Heart Failure from 2005 to 2009. He is associate Editor of the European Heart Journal since 2012.
Dr. Thum is one of the initial pioneers in cardiovascular noncoding RNA research. The current major research focus of Dr. Thum's laboratory is to develop novel diagnostic and therapeutic noncoding RNA-based concepts in cardiovascular medicine and beyond.
Dr. Thum graduated at Hannover Medical School and initially worked in the field of Molecular Cardiology and Clinical Pharmacology. In 2004 he joined the Julius-Maximilians University in Würzburg to finish his training in Internal Medicine and Cardiology. In parallel in 2008 he finished an external PhD program at the National Heart and Lung Institute of the Imperial College in London, U.K. (Prof. P. Poole-Wilson). In October 2009 he became Director and Full Professor of the Institute of Molecular and Translational Therapeutic Strategies (IMTTS) at Hannover Medical School doing translational cardiovascular research.
Adriaan Voors is Professor of Cardiology and specializes in heart failure. Since July 2003, Professor Voors has worked as a Cardiologist in the University Medical Centre Groningen, The Netherlands. In 2007, he became Established Clinical Investigator of the Netherlands Heart Foundation, and in May 2010, he became Professor of Cardiology at the University Medical Center Groningen. Currently, Professor Voors is Director of the Heart Failure Clinic and the Outpatient Clinic of the Department of Cardiology of the University Medical Center Groningen. Professor Voors supervised more than 35 PhD students, mainly on heart failure related topics. He is an editorial board member of the European Journal of Heart Failure, Clinical Research in Cardiology, Netherlands Heart Journal, Cardiovascular Drugs and Therapy, the Journal of Cardiovascular Medicine, and Heart Failure Reviews. He is involved as principal investigator/ executive/steering committee member of 42 clinical trials on novel therapies in acute and chronic heart failure. Prof. Voors was a member of the 2012 ESC Heart Failure Guidelines Committee, and is the co-chair of the 2016 ESC Heart Failure Guidelines. He has authored more than 500 peer-reviewed papers and several books and chapters, his Hirsch-index is 77 and in 2018 his papers were cited more than 6500 times.
Areas of expertiseClinical trials, Mineralocorticoid receptor antagonists, fibrosis, biomarkers.
BiographyCardiologist, Clinical Pharmacologist, Clinical Trialist, Université de Lorraine, France, 2019 visiting Professor at Harvard Medical School, 2017 HFA Lifetime Achievement Award. Contributed to trials in HFrEF (MRAs, beta-blockers, NOACS), and comorbidities (sleep apnea, diabetes, hyperkalemia, CKD). Leading EU granted HF programmes (omics biomarker and fibrosis). Founder Chairmen of CVCT meetings (www.globalcvctforum.com)
Our mission: To reduce the burden of cardiovascular disease
© 2018 European Society of Cardiology. All rights reserved